Cal-Maine
CALM
$0.00
+0.12%
Cal-Maine Foods Inc is the largest producer and marketer of shell eggs in the United States, operating within the Agricultural Farm Products industry. The company is a dominant market leader, distinguished by its vertically integrated operations and a diverse brand portfolio that includes specialty, cage-free, organic, and nutritionally enhanced eggs under names like Egg-Land's Best and Land O' Lakes. The current investor narrative revolves around navigating the cyclical downturn in egg prices, as evidenced by a significant year-over-year revenue decline, while the company strategically deploys its robust cash reserves for acquisitions, such as the recent purchase of Creighton Brothers, to expand its geographic footprint and consolidate its market position during the industry's downcycle.…
CALM
Cal-Maine
$0.00
Related headlines
Investment Opinion: Should I buy CALM Today?
Rating: Hold. The core thesis is that CALM is a high-quality operator in a deep cyclical downturn; its fortress balance sheet provides safety, but the earnings decline is not yet complete, making the stock fairly valued but lacking a near-term catalyst for outperformance. This aligns with the neutral analyst consensus of 'Market Perform'/'Equal Weight'.
Supporting this view are several key data points: 1) The trailing P/E of 3.83x is deceptively low, while the forward P/E of 21.36x is more indicative of normalized earnings expectations. 2) Revenue growth is sharply negative at -19.4% YoY, confirming the downcycle. 3) Profitability remains robust for this stage of the cycle, with a 26.95% gross margin. 4) The company generates substantial free cash flow ($1.17B TTM) and holds $369.5M in cash with zero debt, providing a significant margin of safety.
The two biggest risks are a prolonged egg price depression eroding cash reserves and a failure of acquisitions to generate expected returns. This Hold rating would upgrade to a Buy if the forward P/E compressed below 15x on sustained earnings or if quarterly revenue growth turns positive, signaling cycle stabilization. It would downgrade to a Sell if the stock breaks below its 52-week low of $71.92 on high volume or if quarterly gross margins fall below 20%. Relative to its own volatile history and the uncertain earnings path, the stock is currently fairly valued.
Sign up to view all
CALM 12-Month Price Forecast
CALM is in a holding pattern. The cyclical downturn is real, but the company's financial strength and low valuation provide a buffer against catastrophic loss. The most likely path (60% probability) is a base case of continued range-bound trading as earnings normalize. The stance would turn bullish on evidence of a cycle bottom (e.g., two consecutive quarters of sequential revenue growth). It would turn bearish on a breakdown below the $72 support level, which would signal expectations for a deeper trough. The current neutral stance reflects a wait-and-see approach, favoring investors who can tolerate volatility for a potential cyclical rebound in 12-18 months.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cal-Maine's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
2 analysts
Implied Upside
—
vs. current price
Analyst Count
2
covering this stock
Price Range
$0 - $0
Analyst target range
Analyst coverage is minimal, with only 2 analysts providing estimates, indicating limited institutional research interest which can lead to higher volatility and less efficient price discovery for this mid-cap, cyclical name. The consensus sentiment appears neutral, as reflected in recent institutional ratings from BMO Capital ('Market Perform') and Stephens & Co. ('Equal Weight'), with no recent upgrades or downgrades, suggesting a wait-and-see approach amid the cyclical downturn. The average revenue estimate for the coming period is approximately $3.0 billion, with a wide EPS range from $4.97 to $5.52, highlighting the uncertainty in modeling the earnings trajectory; the lack of a published average price target further underscores the sparse and inconclusive nature of the current analyst coverage.
Bulls vs Bears: CALM Investment Factors
The bull and bear cases for CALM are starkly defined by the cyclical nature of its business. The bull argument rests on a pristine balance sheet, a valuation that appears to price in disaster, and strategic consolidation during weakness. The bear case is driven by the undeniable reality of a sharp earnings decline, weak price momentum, and a forward multiple that implies significant pain ahead. Currently, the bear side has stronger evidence, as the fundamental data (revenue down -19.4%, margin compression) confirms the cyclical downturn is actively unfolding. The single most important tension in the investment debate is the timing and depth of the earnings trough: bulls believe the ultra-low trailing P/E provides a margin of safety, while bears point to the high forward P/E as proof that earnings have much further to fall.
Bullish
- Fortress Balance Sheet: CALM has zero debt and a high current ratio of 6.38, providing immense financial flexibility. This allows the company to make strategic acquisitions like Creighton Brothers and weather cyclical downturns without distress.
- Extremely Low Valuation on Peak Earnings: The trailing P/E ratio of 3.83x is near the historical low for the stock, typically seen at earnings peaks. This suggests the market has already priced in a severe earnings contraction, limiting downside if the cycle troughs higher than feared.
- Strong Profitability Despite Downturn: Even with a -19.4% YoY revenue decline, the company maintained a 26.95% gross margin and generated $102.8M in net income last quarter. This demonstrates robust operational efficiency and pricing power in a normalized environment.
- Strategic M&A to Consolidate Market: The company is using its $1.17B in trailing free cash flow for accretive, cash-funded acquisitions. The recent purchase of Creighton Brothers expands its geographic footprint and strengthens its market leadership during the downcycle.
Bearish
- Severe Cyclical Downturn in Progress: Revenue declined -19.4% YoY last quarter, and gross margin compressed from 48.2% in Q4 2025 to 26.95%. This confirms the company is in the midst of a sharp normalization from historically high egg prices.
- Forward P/E Signals Earnings Collapse: The forward P/E of 21.36x is over 5.5x higher than the trailing P/E, reflecting analyst expectations for a dramatic earnings decline. This indicates the stock is not cheap on a forward basis.
- Persistent Technical Downtrend: The stock is down -18.95% over the past year and -10.84% over six months, significantly underperforming the S&P 500. It trades 39% below its 52-week high of $126.4, indicating sustained selling pressure.
- Limited Analyst Coverage & Sentiment: Only 2 analysts cover the stock, with neutral 'Market Perform' and 'Equal Weight' ratings. The lack of a published average price target and minimal institutional interest suggests limited near-term catalysts for a re-rating.
CALM Technical Analysis
The stock is entrenched in a pronounced downtrend, with a 1-year price change of -18.95% and a 6-month decline of -10.84%, significantly underperforming the broader market. Currently trading at $77.01, the price sits approximately 39% above its 52-week low of $71.92 but a substantial 39% below its 52-week high of $126.4, indicating it is in the lower-middle portion of its annual range and suggesting potential value but within a context of persistent weakness. Recent momentum shows a modest 1-month gain of 6.5%, which contrasts sharply with the 3-month loss of -8.11%, hinting at a possible short-term stabilization or relief rally within the overarching bearish trend, though this nascent positive momentum remains fragile. Key technical support is clearly defined at the 52-week low near $72, while resistance looms overhead at the 52-week high of $126.4; a sustained breakdown below support could signal a new leg down, whereas a meaningful move above it would require a significant fundamental catalyst. The stock's exceptionally low beta of 0.265 indicates it has been roughly 74% less volatile than the S&P 500 over the measured period, which, combined with a high short ratio of 6.57, suggests a defensive, low-volatility profile that may be prone to sharp moves on any positive news.
Beta
0.27
0.27x market volatility
Max Drawdown
-39.2%
Largest decline past year
52-Week Range
$72-$126
Price range past year
Annual Return
-18.9%
Cumulative gain past year
| Period | CALM Return | S&P 500 |
|---|---|---|
| 1m | +0.1% | +4.4% |
| 3m | -8.1% | +8.5% |
| 6m | -10.8% | +9.7% |
| 1y | -18.9% | +28.8% |
| ytd | -1.9% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CALM Fundamental Analysis
Revenue is in a clear cyclical downturn, with the most recent quarterly figure of $769.5 million representing a -19.4% year-over-year decline, continuing a trend from the prior quarter's $922.6 million; this sharp contraction is driven by the normalization of egg prices from historically high levels, with the Non-Specialty Shell Egg segment, representing over $1 billion in annual sales, being the primary drag. Despite the revenue pressure, profitability remains robust with net income of $102.8 million and a gross margin of 26.95% for the quarter, though these figures represent a significant compression from the peak margins seen in prior quarters (e.g., a 48.2% gross margin in Q4 2025), indicating the company is transitioning from super-normal to more normalized profitability. The balance sheet is exceptionally strong, featuring zero debt (debt-to-equity of 0), a high current ratio of 6.38, and substantial liquidity with $369.5 million in cash at the end of the last quarter; this fortress balance sheet is funding both shareholder returns, evidenced by a trailing free cash flow of $1.17 billion, and strategic growth via cash acquisitions like Creighton Brothers.
Quarterly Revenue
$769498000.0B
2025-11
Revenue YoY Growth
-0.19%
YoY Comparison
Gross Margin
+0.26%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CALM Overvalued?
Given the company's substantial net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is remarkably low at 3.83x, while the forward PE is significantly higher at 21.36x; this wide gap reflects the market's expectation that earnings will normalize sharply lower from recent cyclical peaks, with forward estimates baking in a significant earnings decline. Compared to sector averages, the trailing PE of 3.83x is at a deep discount to typical industry multiples, but this is misleading as it compares peak-cycle earnings; a more normalized comparison using the Price-to-Sales ratio of 1.10x may be more relevant, though direct industry average PS data is not available in the provided set. Historically, the stock's own trailing PE has fluctuated wildly with the egg cycle, from over 600x during troughs to as low as 2.17x at peaks; the current 3.83x is near the low end of its historical range, which typically coincides with peak earnings, suggesting the market is pricing in a severe earnings contraction and that the stock may appear cheap on a trailing basis but is fairly valued for the coming downcycle.
PE
3.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -100x~627x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
2.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are dominated by the extreme cyclicality of egg prices, which drives massive earnings volatility. The company's revenue is highly concentrated in a single commodity (shell eggs), with the Non-Specialty segment generating over $1B annually. While the balance sheet is strong, profitability is collapsing, with gross margins falling from 48.2% to 26.95% in just two quarters. The primary risk is that earnings normalize to a level that makes the current forward P/E of 21.36x unjustified, leading to further multiple compression.
Market & Competitive Risks center on valuation compression and a lack of growth narrative. CALM's trailing P/E of 3.83x is a misleading value trap, as it compares peak-cycle earnings. The stock has already suffered a -39% drawdown from its 52-week high, reflecting the market's repricing. As a low-growth, cyclical business in the Consumer Defensive sector, it offers little appeal to growth investors and is vulnerable to being overlooked during market rallies, as evidenced by its -46.8% relative strength vs. the S&P 500 over the past year. The recent news of acquisitions, while strategically sound, has not reversed the negative technical trend.
Worst-Case Scenario involves a deeper-than-expected trough in the egg price cycle, compounded by operational missteps from integrating acquisitions. In this scenario, quarterly earnings could fall towards the low end of analyst estimates ($4.97 EPS), justifying a forward P/E multiple in line with slower-growth food producers, potentially above 25x. This could drive the stock price to re-test and break its 52-week low of $71.92. A realistic downside from the current price of $77.01 is approximately -20% to -25%, reaching the low-$70s, representing a total peak-to-trough drawdown exceeding -45% from the 52-week high.
FAQ
The key risks are, in order of severity: 1) Cyclical Commodity Risk: Earnings are hyper-sensitive to egg prices, which are in a confirmed downtrend with revenue down -19.4% YoY. 2) Valuation Compression Risk: The forward P/E of 21.36x could expand if earnings fall further than expected. 3) Sentiment & Liquidity Risk: Minimal analyst coverage (2 analysts) and a high short ratio (6.57) can lead to exaggerated moves and poor price discovery. 4) Execution Risk: Integrating the Creighton Brothers acquisition during a downcycle could strain management and fail to deliver expected returns, wasting precious cash.
The 12-month forecast for CALM is a range-bound outcome with a neutral bias. The base case (60% probability) sees the stock trading between $75 and $90 as earnings normalize to around $5.25 per share. The bull case (25% probability) targets $95-$110, driven by a faster-than-expected cycle recovery and accretive capital deployment. The bear case (15% probability) sees a drop to $65-$72 if the earnings trough is deeper than feared. The most likely scenario is the base case, which assumes the current cyclical downturn plays out without major new disruptions, leaving the stock stuck until clear fundamental improvement emerges.
CALM's valuation is a tale of two metrics, making it fairly valued on balance. The trailing P/E of 3.83x appears deeply undervalued, but this is a misleading artifact of peak-cycle earnings. The forward P/E of 21.36x, based on expected normalized earnings, is more relevant and suggests the market is pricing in a significant profit decline. Compared to its own history, the stock trades at the low end of its P/E range, which typically occurs at earnings peaks. The market is therefore paying a fair price for a company in cyclical decline, implying it expects EPS to fall roughly 80% from recent highs. It is not cheap on a forward-looking basis.
CALM is a good buy only for a specific type of investor: a patient, value-oriented contrarian comfortable with high earnings volatility. The stock offers a margin of safety via a debt-free balance sheet and a trailing P/E of 3.83x, but this is offset by a high forward P/E of 21.36x signaling expected earnings collapse. With a 25% probability assigned to a bullish scenario targeting $110 and a 15% probability of a bearish scenario targeting $65, the risk/reward is balanced but requires a long time horizon. It is not a good buy for investors seeking growth, income, or short-term gains.
CALM is suitable only for long-term investment with a minimum horizon of 2-3 years. The stock's low beta of 0.265 and cyclical nature make it a poor vehicle for short-term trading, as it lacks the volatility and catalyst-driven price action traders seek. An investor must be willing to hold through the remainder of the earnings downcycle and wait for the subsequent recovery. The company's strong balance sheet and market position support a long-term hold thesis, but the near-term path is one of waiting, not rapid appreciation. This is a classic 'buy and wait' cyclical play.